Skip to content
Peptigraph home

KLOW vs GHK-Cu: What the Research Shows

KLOW and GHK-Cu side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Four-peptide blendNot FDA approved · unstudied blendKLOWUnapproved blend of GHK-Cu, BPC-157, TB-500 and KPV; an FDA Drugs@FDA search for its component GHK-Cu returned no matches, so no approved product was found.[23]Healing & recoveryPre-mixed blendCopper tripeptideInjectable off Category 2 (Apr 2026)GHK-CuCopper tripeptide with mostly topical or cosmetic human data; a small randomized laser-resurfacing study found no statistically significant differences between groups for earlier resolution of erythema.[12]Skin & hair
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider KLOW if…

  • you want the added KPV component, but note its evidence is mouse and cell work only (no human trial found): KPV-treated mice recovered earlier and regained more body weight in DSS colitis.[24]

Consider GHK-Cu if…

  • you want a randomized trial of the topical gel in diabetic foot ulcers (an older study): Median ulcer area closure was 98.5% with the GHK-copper gel versus 60.8% with vehicle (p < 0.05).[25]
  • you want a small randomized skin-care trial with mixed results: patients reported better skin quality (P = .04) but blinded and objective evaluation found no group difference[12]
  • you are tested in sport and want to avoid a WADA-prohibited substance: Klow is prohibited by WADA at all times (check GHK-Cu's own status separately)[2]
Neither is FDA approved for any use in people. KLOW is prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 10 of 12 fields where the two differ. PCAC vote, Jul 2026, Evidence strength are the same or both unknown.

FieldKLOWGHK-Cu
ClassFour-peptide blendCopper tripeptide
Also called—copper peptide, copper tripeptide-1, GHK
CategoryHealing & recoverySkin & hair
FDA statusNot FDA approved · unstudied blendInjectable off Category 2 (Apr 2026)
WADAProhibited by WADA (S0)Contains BPC-157 (named in S0) and TB-500 (S2.3). A blend is prohibited if any component is.WADA status unclearGHK-Cu: This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.
Anti-doping detection
  • BPC-157: A 2023 method detects BPC-157 and five main metabolites in human urine at very low concentrations.PMID 37959764
  • BPC-157: A 2017 anti-doping lab method detects BPC 157 in urine; the peptide was stable in urine for at least 4 days.PMID 28035768
  • TB-500: A horse-racing doping method identified TB-500 and its metabolites in equine urine and plasma after a single dose (animal data, not human).Journal of chromatography. A 2012, PMID 23084823
  • TB-500: A direct-urine screen includes TB-500 among the peptides it can detect, at 50 to 500 pg/mL.PMID 26578461
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeBPC-157: less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717No published half-life foundPubMed search, 11 Oct 2026
Human studies we summarised15 human (9 randomized or controlled) of 65 summarised, across ingredients5 human (2 randomized or controlled) of 15 summarised
Typical study doses
Vial sizes sold80 mg50 mg, 100 mg, 200 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

KLOW and GHK-Cu together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Open the stack page

One peptide with trials versus a four-peptide mix with none

In a laser-resurfacing study of GHK-Cu, computer analysis and blinded evaluators found no statistically significant difference between groups for earlier resolution of erythema.[12]

A systematic review of GHK-Cu says most randomized trials are small and were conducted on facial cosmetic creams.[27]

A systematic review of BPC-157 in orthopaedic sports medicine included 36 studies: 35 preclinical and 1 clinical.[28]

In a rat Achilles tendon study, combined BPC-157 and TB-500 treatment did not confer additional benefits compared with either agent alone.[29]

In a mouse DSS-colitis model, KPV led to earlier recovery and stronger regain of body weight.[24]

Practical and regulatory differences

FDA's safety note on injectable GHK-Cu says there are limited data in humans to inform safety-related considerations.[30]

For KPV, the same FDA page says it has not identified any human exposure data on drug products by any route.[30]

WADA's prohibited list names TB-500, one of KLOW's components, as an example of a derivative of thymosin-ß4.[2]

In a trial of topical GHK-Cu (lamin Gel) for diabetic ulcers, ulcer infections were significantly lower than with vehicle: 7% against 34% in plantar ulcers treated immediately after debridement.[25]

In a rat assay, GHK was rapidly degraded to HK, which was eliminated rapidly.[31]

Common questions

Is KLOW better than GHK-Cu alone?

The cached sources contain no study comparing the two. For GHK-Cu alone, a systematic review says most randomized trials are small and on facial cosmetic creams.[27]

What is the difference between KLOW and GHK-Cu?

GHK-Cu is a single copper-binding tripeptide. KLOW is a mix that also contains BPC-157, TB-500 and KPV. For BPC-157, a systematic review found 1 clinical study among 36.[28]

Is KLOW or GHK-Cu legal to buy?

FDA's compounding safety note says compounded injectable drugs containing GHK-Cu may pose a risk of immunogenicity because of potential aggregation and peptide-related impurities.[30]

Sources

  1. 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
  4. 4Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
  5. 5Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
  6. 6Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
  7. 7Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
  8. 8Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
  9. 9A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
  10. 10Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
  11. 11Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
  12. 12Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.Archives of facial plastic surgery · 2006PMID 16847171Accessed 2 Oct 2026
  13. 13Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2015PMID 25731775Accessed 2 Oct 2026
  14. 14PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) (431 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (humans[mh] OR patients[tiab] OR volunteers[tiab]) (150 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (randomized[tiab] OR clinical trial[pt] OR split-face[tiab]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (wound[tiab] OR hair[tiab] OR skin[tiab] OR wrinkle*[tiab]) (123 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (rat[tiab] OR mice[tiab] OR rats[tiab] OR animal[tiab]) (80 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  20. 20PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (facial[tiab] OR cream[tiab] OR photodamage[tiab] OR volunteers[tiab] OR women[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  21. 21PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (hair[tiab] OR alopecia[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  22. 22PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  23. 23Drugs@FDA (openFDA) search: active ingredient "GHK-Cu"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  24. 24Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
  25. 25Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 1994PMID 17147644Accessed 2 Oct 2026
  26. 26PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  27. 27A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials.Archives of internal medicine research · 2026PMID 42787770Accessed 2 Oct 2026
  28. 28Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
  29. 29Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  30. 30Official web pageOfficial web page · web page
  31. 31Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization.Journal of chromatography. B, Biomedical sciences and applications · 1997PMID 9187381Accessed 2 Oct 2026

Found an error? Report a correction.